troglitazone has been researched along with farglitazar in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blanchard, SG; Brackeen, MF; Brown, KK; Cobb, JE; Collins, JL; Harrington, WW; Hashim, MA; Henke, BR; Hull-Ryde, EA; Kaldor, I; Kliewer, SA; Lake, DH; Leesnitzer, LM; Lehmann, JM; Lenhard, JM; Miller, JF; Mook, RA; Noble, SA; Oliver, W; Orband-Miller, LA; Parks, DJ; Plunket, KD; Szewczyk, JR; Willson, TM | 1 |
| Blanchard, SG; Boswell, EG; Brown, KK; Charifson, PS; Cobb, JE; Collins, JL; Cooper, JP; Dezube, M; Henke, BR; Hull-Ryde, EA; Lake, DH; Lenhard, JM; Oliver, W; Oplinger, J; Parks, DJ; Pentti, M; Plunket, KD; Tong, WQ | 1 |
| Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM | 1 |
| Ajamie, RT; Briere, DA; Brozinick, JT; Devanarayan, V; Hawkins, ED; Henry, JR; Li, Y; Misener, EA; Montrose-Rafizadeh, C; Warshawsky, AM; Wilken, B; Yumibe, NP; Zink, RW | 1 |
| Chen, J; Chen, Q; Jiang, H; Shen, J; Shen, X; Sun, T | 1 |
1 review(s) available for troglitazone and farglitazar
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2000 |
4 other study(ies) available for troglitazone and farglitazar
| Article | Year |
|---|---|
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
Topics: Administration, Oral; Aminopyridines; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; DNA-Binding Proteins; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Ligands; Lipids; Male; Mice; Oxazoles; Propionates; Radioligand Assay; Rats; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Stereoisomerism; Structure-Activity Relationship; Transcription Factors; Transfection; Tyrosine | 1998 |
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.
Topics: Administration, Oral; Animals; Benzoates; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; DNA-Binding Proteins; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Ligands; Lipids; Male; Mice; ortho-Aminobenzoates; Oxazoles; Radioligand Assay; Rats; Receptors, Cytoplasmic and Nuclear; Solubility; Structure-Activity Relationship; Transcription Factors; Tyrosine | 1998 |
Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
Topics: Animals; Blood Glucose; Humans; Hypoglycemic Agents; Mice; Models, Molecular; Peroxisome Proliferator-Activated Receptors; PPAR gamma; Rosiglitazone; Tetrahydroisoquinolines; Thiazolidinediones | 2006 |
A yeast two-hybrid technology-based system for the discovery of PPARgamma agonist and antagonist.
Topics: alpha-Galactosidase; Anilides; Cells, Cultured; Chromans; CREB-Binding Protein; Drug Evaluation, Preclinical; Genes, Reporter; Indomethacin; Ligands; Nuclear Proteins; Oxazoles; Pioglitazone; PPAR gamma; Prostaglandin D2; Protein Binding; Rosiglitazone; Thiazolidinediones; Trans-Activators; Troglitazone; Two-Hybrid System Techniques; Tyrosine; Yeasts | 2004 |